Browse Studies — Arctuva

Phase 2

A Randomized Phase 2/3 Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (HARMONi-GU1)

A Randomized, Open-Label, Multicenter, Phase 2/3 Clinical Study of Ivonescimab in Combination with Enfortumab Vedotin vs Pembrolizumab in Combination with Enfo…

Metastatic Urothelial CarcinomaMetastatic Urothelial Carcinoma (UC)

Estimated

~$75 – $2,800

Actual pay is set by the research site.